A reassessment of the plateauing relationship between T2 lesion load and disability in MS

被引:25
作者
Sormani, Maria Pia [3 ]
Rovaris, Marco [1 ]
Comi, Giancarlo [2 ]
Filippi, Massimo [1 ]
机构
[1] Univ Hosp San Raffaele, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, I-20132 Milan, Italy
[2] Univ Hosp San Raffaele, Dept Neurol, Inst Expt Neurol, Div Neurosci, I-20132 Milan, Italy
[3] Univ Genoa, Biostat Unit, Dept Hlth Sci DISSAL, I-16126 Genoa, Italy
关键词
PROGRESSIVE MULTIPLE-SCLEROSIS; DISEASE-ACTIVITY; MRI; MULTICENTER; IMPAIRMENT; TRIAL;
D O I
10.1212/WNL.0b013e3181c06679
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: A recent cross-sectional study has shown a plateauing relationship between T2 lesion volume (T2LV) and disability in patients with multiple sclerosis ( MS). In this analysis, which also included longitudinal observations, we investigated whether such a relationship is a consequence of the decreased frequency of "inflammatory" events occurring in more disabled patients, rather than reflecting their disability status. Methods: The placebo arms of 2 clinical trials were analyzed. One cohort consisted of 548 patients with relapsing-remitting (RR) MS enrolled in a 14-month, randomized, double-blind, placebo-controlled trial of oral glatiramer acetate. The second cohort consisted of 358 patients with secondary progressive (SP) MS still experiencing relapses enrolled in a 3-year, randomized, double-blind, placebo-controlled trial of interferon beta-1b. Results: At baseline, T2LV was associated with disease duration (p < 0.001), age at MS onset (p < 0.001), and disability (p < 0.001). The relationship between baseline T2LV and Expanded Disability Status Scale (EDSS) was not significantly different between patients with RRMS and SPMS. At a multivariate analysis, T2LV change was associated with the number of on-trial relapses (p < 0.001) and age at MS onset (p = 0.02). The correlations of T2LV change with baseline EDSS and EDSS changes were not significant. Conclusions: We showed that the plateauing relationship between T2 lesion volume and disability in multiple sclerosis is not always present and is likely due to the reduced frequency of "inflammatory" events in the most common form of secondary progressive multiple sclerosis. Neurology (R) 2009; 73: 1538-1542
引用
收藏
页码:1538 / 1542
页数:5
相关论文
共 11 条
[1]   MRI in multiple sclerosis: current status and future prospects [J].
Bakshi, Rohit ;
Thompson, Alan J. ;
Rocca, Maria A. ;
Pelletier, Daniel ;
Dousset, Vincent ;
Barkhof, Frederik ;
Inglese, Matilde ;
Guttmann, Charles R. G. ;
Horsfield, Mark A. ;
Filippi, Massimo .
LANCET NEUROLOGY, 2008, 7 (07) :615-625
[2]   Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study [J].
Filippi, M ;
Wolinsky, JS ;
Comi, G .
LANCET NEUROLOGY, 2006, 5 (03) :213-220
[3]   Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis [J].
Filippi, M ;
Gawne-Cain, ML ;
Gasperini, C ;
vanWaesberghe, JH ;
Grimaud, J ;
Barkhof, F ;
Sormani, MP ;
Miller, DH .
NEUROLOGY, 1998, 50 (01) :238-244
[4]   Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? [J].
Goodin, DS .
ANNALS OF NEUROLOGY, 2006, 59 (04) :597-605
[5]   Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis [J].
Kappos, L ;
Polman, C ;
Pozzilli, C ;
Thompson, A ;
Dahlke, F ;
Knight, R ;
Hern, J ;
Coleman, R ;
Gerrie, L ;
Cooper, G ;
Moore, J ;
Boringa, J ;
van Oosten, B ;
Ronner, H ;
Schrijver, H ;
Truyen, L ;
Montalbán, J ;
Río, J ;
Tintoré, M ;
Jacas, C ;
Marzo, E ;
Lechner-Scott, J ;
Huber, S ;
Lienert, C ;
Brunnschweiler, H ;
Hawkins, S ;
Droogan, A ;
McDonnell, G ;
Duddy, M ;
McKinstry, S ;
Altenkirch, H ;
Baum, K ;
Einhäupl, K ;
Marx, P ;
Poewe, W ;
Walter, G ;
Akman, H ;
Brockmeier, B ;
Scherer, P ;
Zschenderlein, R ;
Schmierer, K ;
Gelderblom, H ;
Hartmann, A ;
Stapf, C ;
Lüschow, A ;
Mackert, B ;
Schumacher, H ;
Masuhr, F ;
Hempel, T ;
Zimmermann, R .
LANCET, 1998, 352 (9139) :1491-1497
[6]   Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS [J].
Kappos, L ;
Polman, C ;
Pozzilli, C ;
Thompson, A ;
Beckmann, K ;
Dahlke, F .
NEUROLOGY, 2001, 57 (11) :1969-1975
[7]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[8]   MRI T2 lesion burden in multiple sclerosis - A plateauing relationship with clinical disability [J].
Li, DKB ;
Held, U ;
Petkau, J ;
Daumer, M ;
Barkhof, F ;
Fazekas, F ;
Frank, JA ;
Kappos, L ;
Miller, DH ;
Simon, JH ;
Wolinsky, JS ;
Filippi, M .
NEUROLOGY, 2006, 66 (09) :1384-1389
[9]   GADOLINIUM ENHANCEMENT INCREASES THE SENSITIVITY OF MRI IN DETECTING DISEASE-ACTIVITY IN MULTIPLE-SCLEROSIS [J].
MILLER, DH ;
BARKHOF, F ;
NAUTA, JJP .
BRAIN, 1993, 116 :1077-1094
[10]   Secondary progressive multiple sclerosis: current knowledge and future challenges [J].
Rovaris, M ;
Confavreux, C ;
Furion, R ;
Kappos, L ;
Comi, G ;
Filippi, M .
LANCET NEUROLOGY, 2006, 5 (04) :343-354